A 78-year-old man with a carcinoembryonic antigen (CEA) level of 11.0 ng/mL but no evidence of metastasis underwent a right hemicolectomy (surgical pathology showed a 5.5-cm adenocardinoma with 0 of 19 lymph nodes positive for cancer). At 6 months, CEA was 3.0 ng/mL. At 12 months, CEA was 5.1 ng/mL and then 6.1 ng/mL with repeat testing. What would you do next?
This study used the Drugs@FDA database to review FDA-approved “breakthrough” therapies from 2012 to 2017 (characterizing the pivotal clinical trials that serve as the basis of FDA approval), and premarket development and review times to assess the strength of evidence supporting breakthrough approvals.
This 24-month cohort study tracks high school students in Los Angeles County, California, who were not initially assessed as having ADHD symptoms to compare frequency of use of digital media platforms with experiencing ADHD symptoms.
This JAMA Patient Page describes the US Preventive Services Task Force recommendations on assessment for cardiovascular disease using nontraditional risk factors.
You currently have no searches saved.